A new liquid biopsy approach developed by Johns Hopkins Kimmel Cancer Center investigators could revolutionize brain cancer ...

The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...

Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John Heymach, ...

Zongertinib elicited meaningful results in previously treated patients with HER2-mutated, advanced non–small cell lung cancer ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

Cogent Biosciences (COGT) announced preclinical data from four pipeline programs during poster sessions at the American Association for Cancer ...

In a recent study published in Small, researchers at the University of Michigan developed nanodiscs designed to target ...

"You should have a minimum of three bowel movements per week, preferably one a day. A patient from the ER started vomiting ...

Scientists from St. Jude Children's Research Hospital and the Medical College of Wisconsin have created a data science framework to better understand how cells travel through the body.